Who is sponsoring NCT04061746?

NCT04061746 is sponsored by Medical University of South Carolina.

What drugs are being tested in NCT04061746?

Interventions in NCT04061746: Mesenchymal Stem Cells (MSCs), Placebo Infusion (Plasmalyte A with 0.5% human serum albumin).

What condition does NCT04061746 study?

NCT04061746 studies Diabetes Mellitus, Type 1.

Is NCT04061746 still recruiting?

NCT04061746 is currently recruiting now. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT04061746

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

Recruiting now Phase 1 Last updated 3 April 2026

What this trial tests

Phase 1 trial testing Mesenchymal Stem Cells (MSCs) in Diabetes Mellitus, Type 1 in 60 participants. Currently enrolling.

Timeline

27 February 2020

Primary endpoint
15 April 2026

30 May 2027

Quick facts

Lead sponsor	Medical University of South Carolina
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	27 February 2020
Primary completion	15 April 2026
Estimated completion	30 May 2027
Sites	1 location across United States

Drugs / interventions tested

Mesenchymal Stem Cells (MSCs) — full drug profile →
Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)

Conditions studied

Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →

Sponsor

Medical University of South Carolina

Who can join

Adults 18 to 40, any sex, with Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to determine the safety and efficacy of fresh metabolically active allogeneic umbilical cord-derived mesenchymal stromal cells (UC-MSCs) for the treatment of new-onset type 1 diabetes (T1D) and to understand the mechanisms of protection. If proven effective, such a strategy can be used as a therapeutic option for T1D patients and potentially other autoimmune disorders.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Identifying the Therapeutic Significance of Mesenchymal Stem Cells.
Mishra VK, Shih HH, Parveen F, Lenzen D, et al · · 2020 · cited 115× · PMID 32384763 · DOI 10.3390/cells9051145
Cell therapies in the clinic.
Wang LL, Janes ME, Kumbhojkar N, Kapate N, et al · · 2021 · cited 99× · PMID 34027097 · DOI 10.1002/btm2.10214
Stem Cell-Based Clinical Trials for Diabetes Mellitus.
de Klerk E, Hebrok M. · · 2021 · cited 78× · PMID 33716982 · DOI 10.3389/fendo.2021.631463
Stem cells differentiation into insulin-producing cells (IPCs): recent advances and current challenges.
Silva IBB, Kimura CH, Colantoni VP, Sogayar MC. · · 2022 · cited 53× · PMID 35840987 · DOI 10.1186/s13287-022-02977-y
The Clinical Trials of Mesenchymal Stromal Cells Therapy.
Kouchakian MR, Baghban N, Moniri SF, Baghban M, et al · · 2021 · cited 30× · PMID 34745268 · DOI 10.1155/2021/1634782
Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study.
Kassem DH, Kamal MM. · · 2020 · cited 27× · PMID 33198815 · DOI 10.1186/s13287-020-01996-x
Current advancements in cellular immunotherapy for autoimmune disease.
Berry CT, Frazee CS, Herman PJ, Chen S, et al · · 2025 · cited 15× · PMID 39821376 · DOI 10.1007/s00281-024-01034-5
Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options.
Mello DB, Mesquita FCP, Silva Dos Santos D, Asensi KD, et al · · 2024 · cited 15× · PMID 38892249 · DOI 10.3390/ijms25116063

Verify or expand the search:

Other trials of Mesenchymal Stem Cells (MSCs)

Trials testing the same drug.

NCT06149832 — Treatment of Oral Chronic Graft-versus-host Disease With Human Umbilical Cord Mesenchymal Stem Cell Dressing · Phase 4 · unknown
NCT05284604 — Mesenchymal Stem Cells for Age-Related Frailty · Phase 1, PHASE2 · withdrawn
NCT04361942 — Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells · Phase 2 · completed
NCT02804945 — Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies · Phase 1 · completed

Other recruiting trials for Diabetes Mellitus, Type 1

Currently open trials in the same condition.

NCT07325461 — Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes · NA · recruiting
NCT07305805 — A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes · Phase 1 · recruiting
NCT06282055 — Trajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes · recruiting
NCT06325202 — Closed Loop and Education for Hypoglycemia Awareness Restoration · NA · recruiting
NCT07160816 — A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar · recruiting

Other Medical University of South Carolina trials

Trials by the same sponsor.

NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04061746 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04061746.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing